From the Journals

Cardiovascular disease risk higher in patients with schizophrenia, metabolic syndrome


 

FROM THE MEDICAL JOURNAL OF THE ISLAMIC REPUBLIC OF IRAN

Metabolic syndrome is common among patients with schizophrenia, and those with metabolic syndrome are at significantly higher risk for cardiovascular disease, according to Shadi Naderyan Fe’li of the department of biostatistics and epidemiology at Shahid Sadoughi University of Medical Sciences in Yazd, Iran, and associates.

The cross-sectional study, performed on 100 patients with schizophrenia (83 men, 17 women), was published in the Medical Journal of the Islamic Republic of Iran. The overall prevalence of metabolic syndrome was 27% (men, 21.7%; women, 52.9%); the most common component of metabolic disorder was low HDL cholesterol in males and abdominal adiposity in females.

Based on Framingham Risk Scores, 76% of study participants had a low risk of cardiovascular disease, 16% had intermediate risk, and 8% had high risk. However, patients were almost twice as likely to have intermediate or high risk of cardiovascular disease if they also had metabolic syndrome (P = .042).

“Considering the findings of this study as well as other recent reports, psychiatrists and health care staff should be informed about the potential metabolic side effects of antipsychotics and unhealthy lifestyles among these patients. Furthermore, regular monitoring of metabolic risk factors is suggested. In addition, medical and behavioral interventions should be conducted for patients with [metabolic syndrome],” the investigators concluded.

The investigators reported that they had no conflicts of interest.

SOURCE: Fe’li SN et al. Med J Islam Repub Iran. 2019 Sep 16. doi: 10.34171/mjiri.33.97.

Recommended Reading

Personal health records help mentally ill patients with comorbidities access medical services
Type 2 Diabetes ICYMI
Class of 2015: New drugs projected to earn billions and billions
Type 2 Diabetes ICYMI
Researchers highlight gaps in diabetes screening in patients on antipsychotics
Type 2 Diabetes ICYMI
Antipsychotics may double to triple diabetes risk in youth
Type 2 Diabetes ICYMI
VIDEO: Lifestyle intervention blocks antipsychotic-associated weight gain
Type 2 Diabetes ICYMI
Statement warns of drugs causing or exacerbating heart failure
Type 2 Diabetes ICYMI
Type 2 diabetes peer-led intervention in primary care tied to improved depression symptoms
Type 2 Diabetes ICYMI
Liraglutide produced cardiometabolic benefits in patients with schizophrenia
Type 2 Diabetes ICYMI
Targeting obesity could slow brain aging in psychosis
Type 2 Diabetes ICYMI
Address physical health risks of people with SMI
Type 2 Diabetes ICYMI